Pre-ASCO China Summit & Dinner

• Dr. Li Yan, Managing Director, USCACA; CMO, Brii Biosciences

• Dr. Melvin Chua Lee Kiang, Associate Professor, National Cancer Centre Singapore; Chair-Elect, Program Committee, ASCO Breakthrough 2023
• Dr. Patricia Keegan, Chief Medical Officer, TopAlliance Biosciences
• Dr. Ying Liu,
• John Moller, Novotech CEO
• Dr. Haiqiang Mai, Sun Yat Sen University Cancer Center
• Martin S. Olivo, MD, MSc, SystImmune  CMO
• Dr. Jingdong Qin,
• Dr. Lillian Siu, Professor, University of Toronto; Chair, Program Committee, ASCO Breakthrough 202
• Dong Shen, MD, PhD, Founder & President of RNAimmune, Inc
• Anthony W. Tolcher, M.D., FRCPC, FACP, NEXT Oncology CEO & Founder
• Dr. Yan Wang,VP of Clinical Research, Remegen Inc.
• Peter Paul Yu, MD, FACP, FASCO, Physician-in-Chief of the Hartford HealthCare Cancer Institute, Chair, Co-Host Committee, ASCO Breakthrough 2023

Dr Chua is a Clinician-Scientist, who is supported by the NMRC Clinician-Scientist Award. His research focuses on the development of Phase II-III clinical trials in nasopharyngeal (NPC) and prostate cancers. He also runs a laboratory that is involved in data science and omics analytics that help with therapeutic and biomarker discovery for these cancer types. He serves as Associate Professor (Tenured) of Duke-NUS Medical School, Singapore; Visiting Professor of Zhongnan Hospital of Wuhan University, China.

His key accomplishments include: ASCO-CSCO International guidelines on the treatment of locoregionally-advanced NPC; Co-Lead investigator of the randomised controlled trial of induction gemcitabine-cisplatin in high-risk locoregionally-advanced NPC; Co-Lead investigator of the randomised controlled trial of consolidation radiotherapy in patients with metastatic NPC who manifest a good response to palliative chemotherapy.

Currently, Dr Chua co-leads the Singapore NPC Large Collaborative Grant, where he leads a platform trial – RIBBON: tReatment Individualisation By eBv stratificatiOn in Locally Advanced Nasopharyngeal carcinoma: A multi-arm platform study – for locoregionally advanced NPC and recurrent-metastatic NPC.

Dr Chua also received numerous honours such as SingHealth Excellence Distinguished Researcher Award, Conquer Cancer Foundation ASCO Merit Award, NMRC Clinician-Scientist Award (Investigator), Fellow of the Royal College of Radiologists, and Fellow of the Academy of Medicine Singapore (FAMS).

Dr. Patricia Keegan, is the Chief Medical Officer at TopAlliance Biosciences, Inc., a subsidiary of Shanghai Junshi Biosciences. Junshi Biosciences and TopAlliance Biosciences are focused predominantly in the development of immunotherapeutics for the treatment of cancer, with the lead candidate drug (toripalimab, an anti-PD-1 blocking antibody) the first PD-1 antibody approved in China in 2018, with multiple new indications since, and is under BLA review at the US FDA for the treatment of nasopharyngeal cancer.  Prior to joining TopAlliance Biosciences, Inc. since August 2020. Prior to joining TopAlliance, Dr. Keegan held multiple positions at the U.S. Food and Drug Administration over 30 years. Her most recent position was Acting Associate Director of Medical Policy Oncology Center for Excellence (OCE), Office of the commissioner; as well as 16 years as the Division Director of Oncology Products; 4 years as Deputy Director Division of Clinical Trial Design and Analysis; and 8 years as Chief and Medical officer at Oncology Branch. Prior to joining FDA, Dr. Keegan was a Clinical Assistant Professor of Medicine in Hematology and Medical Oncology at University of North Carolina at Chapel Hill. Dr. Keegan received her Bachelor of Science in Biology from University of Illinois Champaign-Urbana. She earned her medical degree from Loyola University Stritch School of Medicine, where she also completed a residency in internal medicine and completed a fellowship in medical oncology at Roswell Park Memorial Institute, Buffalo, New York.

Dr. Siu is a senior medical oncologist at Princess Margaret Cancer Centre since 1998, and has been a Professor of Medicine at the University of Toronto since 2009. She is the Director of the Phase I Program and Co-Director of the Bras and Family Drug Development Program at Princess Margaret Cancer Centre, and holds the BMO Chair in Precision Genomics (2016-2026). She is also the Clinical Lead for the Tumor Immunotherapy Program at Princess Margaret Cancer Centre. Dr. Siu served on the Board of Directors for the American Society of Clinical Oncology (ASCO) for a four-year term (2012-2016); she also served on the American Association for Cancer Research (AACR) Board of Directors for a three-year term (2017-2020).

Dr. Siu’s major research focus is in the area of new anticancer drug development, particularly with respect to phase I trials and head and neck malignancies. She is the Principal Investigator of a phase I cooperative agreement UM1 award sponsored by the United States National Cancer Institute. In addition to her active research in early phase clinical trials, she has been leading genomics initiatives and immuno-oncology trials at the Princess Margaret Cancer Centre. Together, the three programs of drug development, cancer genomics and tumor immunotherapy form a triad of synergy that supports the institution’s core vision to deliver precision cancer medicine. Internationally, Dr. Siu was the recipient of the US NCI Michaele C. Christian Award in Oncology Drug Development in 2010. She has been awarded the TAT 2020 Honorary Award for contributions in the development of anticancer drugs. Dr. Siu has published over 370 peer-reviewed manuscripts, and she is currently the co-Editor-in-Chief for AACR’s newest journal Cancer Research Communications, and is on the editorial board for Cell and Cancer Cell. Dr. Siu is the Chair of the Program Committee for 2023 ASCO Breakthrough meeting in Yokohama, Japan.

Dr. Peter Paul Yu is Physician-in-Chief of the Hartford HealthCare Cancer Institute and Clinical Member Memorial Sloan Kettering Cancer Center. He is a graduate of the combined undergraduate and medical school Program in Liberal Medical Education at the Warren Alpert Medical School, Brown University and completed his medical oncology fellowship at Mount Sinai Medical Center under Dr. James Holland. Dr. Yu studied EGFR signal transduction during a postdoctoral fellowship at Memorial Sloan-Kettering Cancer Center in the laboratory of Dr. John Mendelsohn.

Dr. Yu served as President and Board Chairman of the American Society of Clinical Oncology (ASCO) 2014-2015. During his presidency, ASCO launched two new journals, JCO Global Oncology and JCO Clinical Cancer Informatics and CancerLinQ, a digital health ecosystem. Past ASCO activities have included Board Member, Chair of the Clinical Practice Committee, Chair HIT Work Group, Chair Awards Committee, and member of the Cancer Research, Integrated Media, Grant Selection, Audit, Nominating, Scientific Program, Education and Quality of Care committees. In 2017, he was the inaugural Education Committee Global Oncology track leader and in 2019 chair of ASCO’s first international symposium, Breakthrough, which focuses on the emerging clinical innovation in oncology.

Dr. Yu has extensive experience in public policy, interacting with Congress and the Centers for Medicare & Medicaid Services (CMS) on payment reform which included multiple major legislative bills: Medicare Modernization Act (MMA), American Recovery and Reinvestment Act (ARRA), the Affordable Care Act (ACA), the Medicare Access and CHIP Reauthorization Act (MACRA) and 21ST Century Cures Act. He was involved with the development of ASCO’s Patient-Centered Oncology Payment Model (PCOP) and the ASCO Value Based Framework for oncology therapeutics.

His involvement with professional societies and regulatory agencies include the College of American Pathologists Cancer Biomarker Reporting Committee, the Society for Immunotherapy of Cancer Value-Based Subcommittee, Global Alliance for Genomics & Health, Hutchinson Institute for Cancer Outcomes Research External Advisory Board, the California Department of Health California Cancer Registry External Advisory Committee and the American Joint Committee on Cancer.

Dr. Yu has served as co-chair of the Commission for Certification of Health Information Technology (CCHIT) Oncology work group, co-chair of the AMA-RAND Clinical Decision Support Oncology work group under contract to the Office of the National Coordinator for Health Information Technology, co-chair of the ASCO-NCI CORE informatics project and has participated in several Institute of Medicine health information technology workshops. Dr. Yu is an elected member of the Epic Systems Oncology Steering Board. From 2014-2020 he served on the Board of Governors of ASCO’s CancerLinQ, a rapid learning health system aggregating data across electronic health record systems. He is Associate Editor of JCO Clinical Cancer Informatics.

Dr. Yan is a seasoned drug developer. He held executive positions at GSK, Merck, and Johnson & Johnson, most recently, VP Global Oncology Head Unit Physician of GSK. He contributed to the development and approval of numerous medicines including Keytruda for China. He firmly believes in the power of global collaboration. He is a graduate of Peking University Medical College where he is an adjunct professor. He is an alumnus of Harvard Business School Enterprise Leadership program.

Ying Liu is Dr. Satish C. & Asha Saxena Chair Professor and Director of Graduate Studies in the Department of Chemical Engineering and affiliated with the Departments of Biomedical Engineering and Pharmaceutical Sciences at the University of Illinois Chicago (UIC). She is the founder and co-founder of several biotech startup companies.

Ying Liu received her B.S. from Tsinghua University in Beijing, China and her Ph.D. from Princeton University. Ying Liu has been the recipient of several awards, including National Science Foundation CAREER Award, UIC Researcher and Scholar of the Year Rising Star Award, and Engineering Research Award.

Hai-Qiang Mai is a Professor of Radiation Oncology, a PhD Supervisor, and the chief director of the department of nasopharyngeal carcinoma in Sun Yat-sen University Cancer Center, China. Dr. Mai is proficient in treating nasopharyngeal carcinoma, and his research is mainly focused on the prognosis and individualized treatment for nasopharyngeal carcinoma.

Dr. Mai graduated from Sun Yat-sen University of Medical Science in 1996, and then gained his MD and PhD degrees in Clinical Oncology in Sun Yat-sen Cancer Center. He also worked as a postdoc in University of Florida Shands Cancer Center, USA from 2001 to 2002, and later completed clinical fellowship in the department of Clinical Oncology, the Hong Kong University.

Being a chief physician and deputy director of Department of Nasopharyngeal Carcinoma, Sun Yat-sen Cancer Center, Dr. Mai has made great efforts in treating and studying nasopharynx cancer, which has been acknowledged by both his patients and peers. As a principle investigator, Dr. Mai has been conducting multiple scientific researches since 2006, including the National Science Fund for Distinguished Young Scholars and the National Key Research and Development Program of China. Under his guidance, 86 peer-reviewed papers are published in prestigious medical journals, such as Lancet Oncol, J Clin Oncol, J Natl Cancer Inst, Clin Cancer Res, etc, and some of his researches has been adopted by international guidelines. Besides, he also plays a role in editorial and journal-review activities.

Dr. Mai has won the Chinese National Science Fund for Distinguished Young Scholars in recognition of his achievements. His other highlighted awards include Leading Talents of Scientific and Technological Innovation of Ten Thousand Talents Plan, Young and Middle-aged Leading Talents of Scientific and Technological Innovation, Chinese Young Scientist Award in Oncology, Leading Talents of Science and Technology Innovation in Guangdong Province, New-Century Excellent Researcher Award from Education Ministry, National Training Candidate of Thousand-Hundred-Ten Project in Guangdong Province, etc.

Dr. Martin S. Olivo is a highly accomplished medical oncologist that has already achieved a remarkable amount in the progression of oncology therapeutics and has more than two decades of experience in oncology clinical research and global drug development. Dr. Olivo is the Chief Medical Officer at SystImmune, where he leads all oncology clinical efforts outside of China. Prior to joining SystImmune, he served as Chief Medical Officer for Protara Therapeutics, Inc. Before these roles, Dr. Olivo led clinical efforts in metastatic breast cancer therapeutics development as the Vice President of Clinical Development at Gilead Sciences, Inc., formerly Immunomedics, Inc. Earlier, Dr. Olivo served as the Global Clinical Lead at Daiichi Sankyo Cancer Enterprise, where he established a comprehensive clinical development plan for an early-stage oncology product candidate (Patritumab Deruxtecan) with applications in lung and breast cancer. Prior to that, Dr. Olivo served in several roles with increasing responsibilities in the oncology group at Eisai Inc., where he was the International Program Team Leader for Halaven, a major drug now used to treat breast cancer. Before that, he spent 2-year tenure with CELGEN (formerly Abraxis), working with Abraxane in NSLCC and Breast Cancer, as well as working in the first phase 1 with Nab Rapamycin, now FDA-approved for patients with Pecoma.

Dr. Olivo received his M.D. from the University of Buenos Aires and his M.S. in Clinical and Pharmacological Research from Austral University in Buenos Aires. He completed advanced training as a Clinical Oncologist at the University of Salvador. Dr. Olivo then held various academic and clinical positions at the School of Medicine at the University of Buenos Aires, Hospital "Dr. Enrique Tornú" and the National Cancer Institute of Canada Clinical Trials Group.

Dr. Dong Shen is the 20th president of the Chinese Biopharmaceutical Association (CBA). Dr. Shen graduated with PhD from Johns Hopkins University School of Medicine and MD from Shanghai Jiaotong University School of Medicine. His PhD supervisor is Dr. Bert Vogelstein, a world authority in oncology.

Dr. Shen has led several TCGA projects, including a breast cancer project with Elaine Mardis of the WashU Genonme Institute in St. Louis, an AML project with Tim Lay and Matt Walter of Washington University School of Medicine in St. Louis, and an MDS Project with Tim Graubert of Harvard Medical School. Dr. Shen has extensive cancer vaccine and drug development experience in AstraZeneca and Johnson and Johnson, having led projects across multiple therapeutic areas with high unmet medical need. In March 2020, Dr. Shen founded RNAimmune, Inc, and led the team that has completed $40 million financing, which will further promote the research and development of mRNA vaccines and therapeutics for infectious diseases, cancers and rare diseases. In April 2023, RNAimmune has received a clearance from the United States Food & Drug Administration (FDA) cleared its Investigational New Drug (IND) application a Phase I clinical trial for RV-1730, a SARS-CoV-2 vaccine booster candidate.

Dr. Anthony Tolcher is a medical oncologist and co-founder of NEXT Oncology. He is dedicated to the development of new anticancer agents — including clinical trials and therapies — for patients looking for their next option now that their current cancer therapy is no longer working to their benefit. Dr. Tolcher is proud that the NEXT Oncology team scours the world to bring the best new agents back to its patients and centers.

This is much more than a job for Dr. Tolcher. It is his life’s work.

BACKGROUND:

He is a graduate of the University of British Columbia in Vancouver, Canada. He performed his residency in internal medicine at the University of Toronto and his fellowship in oncology at the University of British Columbia. He followed this with a research fellowship at the National Cancer Institute in Bethesda, Maryland.

He was a Fogarty Fellow at the National Institute of Health and received the Murray Muirhead Award for humanitarian and academic excellence and the Goel Prize in Medicine for excellence in the Clinical Disciplines. He is a Fellow of the Royal College of Physicians of Canada; a Diplomate of the American Board of Internal Medicine and Medical Oncology; and a member of the American College of Physicians, and the American Society of Clinical Oncologists. He also serves as a member of the American Society of Clinical Oncology Scientific Program Committee and the Cancer Education Committee.

Event Venue

Pre-ASCO China Summit& Dinner, 320 S. Canal St., Chicago, United States